Fetching results...
0 items found

The content in the Resource Centre is not accredited.

567: A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISE

Dr. H. (Heather) Payne
Payne H.1, Robinson A.2, Rappe B.3, Hilman S.4, De Giorgi U.5, Joniau S.6, Bordonaro R.7, Mallick S.8, Dourthe L.9, Mira Flores M.10, Gumà J.11, Baron B.12, Duran A.13, Pranzo A.13, Serikoff A.14, De Santis M.15
1University College Hospital London, Dept. of Oncology, London, United Kingdom, 2Royal Sussex County Hospital, Sussex Cancer Center, Brighton, United Kingdom, 3ASZ Aalst, Dept. of Urology, Aalst, Belgium, 4Weston General Hospital, Dept. of Oncology, Weston-super-Mare, United Kingdom, 5Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST), Dept. of Oncology, Meldola, Italy, 6University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 7Garibaldi Nesima Hospital, Dept. of Oncology, Catania, Italy, 8Saint-Michel Clinic, Dept. of Urology, Toulon, France, 9Saint Anne Clinic, Dept. of Medical Oncology, Strasbourg, France, 10Arnau de Vilanova University Hospital, Dept. of Radiotherapy Oncology, Lleida, Spain, 11Saint Joan University Hospital, IISPV, URV, Oncology Institute of Southern Catalonia, Reus, Spain, 12Astellas Pharma Inc., Leiden, The Netherlands, 13Astellas Pharma Inc., Chertsey, United Kingdom, 14Astellas Pharma Inc., Levallois-Perret, France, 15Charité University Hospital, Dept. of Urology, Berlin, Germany
35th Annual EAU Congress - Virtual (EAU20V)
17 July 2020
Prostate Cancer, metastatic - Treatment, Drug Treatment
  • © 2021 European Association of Urology
  • Disclaimer